BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38287511)

  • 61. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
    Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
    J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors?
    Bolhassani A; Shahbazi S; Agi E; Haghighipour N; Hadi A; Asgari F
    Mol Immunol; 2019 Apr; 108():102-110. PubMed ID: 30802787
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
    Liu H; Wu BH; Rowse GJ; Emtage PC
    Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
    Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
    Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
    Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
    Front Immunol; 2020; 11():188. PubMed ID: 32133000
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
    Decrausaz L; Domingos-Pereira S; Duc M; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D
    Int J Cancer; 2011 Aug; 129(3):762-72. PubMed ID: 21384340
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.
    Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D
    Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity.
    Ding Y; Seow SV; Huang CH; Liew LM; Lim YC; Kuo IC; Chua KY
    Immunology; 2009 Sep; 128(1 Suppl):e881-94. PubMed ID: 19740349
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles.
    Ali AA; McCrudden CM; McCaffrey J; McBride JW; Cole G; Dunne NJ; Robson T; Kissenpfennig A; Donnelly RF; McCarthy HO
    Nanomedicine; 2017 Apr; 13(3):921-932. PubMed ID: 27979747
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.
    Bubenik J
    Curr Cancer Drug Targets; 2008 May; 8(3):180-6. PubMed ID: 18473731
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV
    Dorta-Estremera S; Chin RL; Sierra G; Nicholas C; Yanamandra AV; Nookala SMK; Yang G; Singh S; Curran MA; Sastry KJ
    Cancer Res; 2018 Sep; 78(18):5327-5339. PubMed ID: 30054333
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.
    Domingos-Pereira S; Roh V; Hiou-Feige A; Galliverti G; Simon C; Tolstonog GV; Nardelli-Haefliger D
    Oncoimmunology; 2021 Apr; 10(1):1912473. PubMed ID: 33907631
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
    Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
    Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems.
    Tahamtan A; Ghaemi A; Gorji A; Kalhor HR; Sajadian A; Tabarraei A; Moradi A; Atyabi F; Kelishadi M
    J Biomed Sci; 2014 Jul; 21(1):69. PubMed ID: 25077570
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.